真实世界中疏血通注射液治疗脑梗死疗效分析

Based on propensity score methods analysis of outcomes of parenterally administered Shuxuetong in treatment of cerebral infarction

该研究以全国18家三级甲等医院的HIS为数据来源，将HIS中107723例病例分为使用疏血通组和未使用疏血通组，从每组中再选择年龄18—80岁、患有脑梗死、治疗结局明确的病例。最终，使用疏血通组7520例，未使用疏血通组3353例。采用倾向性评分法平衡2组间的混杂因素，通过3种Logistie回归方法比较2组间治疗脑梗死疗效的差异。3种方法结果均显示，使用疏血通组的治愈率显著高于未使用疏血通组，统计学显示有显著性差异。因此，基于现有数据，证明在治疗脑梗死方面，常规治疗联合应用疏血通的疗效优于未联合应用疏血通的疗效。

Hospital information system （HIS） data from 18 hospitals was analyzed. 107 723 cases were divided into two groups,those that received Shuxuetong and those that did not. Patients, 18 to 80 years old, suffering from cerebral infarction, whose treatment outcome was clear were selected. Resulting in 7 520 cases in the treatment group and 3 353 who did not receive parenterally administered Shuxuetong. Using propensity score, confounding factors were balanced between the two groups, three logistic regression methods were used to compare the groups following treatment for cerebral infarction. The three methods of comparison indicated that the use of Shuxuetong significantly increased cure rates compared to the control group. Therefore, based on existing data, for the treatment of cerebral infarction, the outcomes are more effective when combination therapy including Shuxuetong is used.